Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet Lond Engl. 2005;365(9472):1687–717.

Article  Google Scholar 

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet Lond Engl. 2011;378(9793):771–84.

Article  CAS  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.

Article  Google Scholar 

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–38.

Article  CAS  PubMed  Google Scholar 

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, et al. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med. 2021;385(5):395–405.

Article  CAS  PubMed  Google Scholar 

Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res BCR. 2011;13(3):R64.

Article  PubMed  Google Scholar 

Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30-66.

Article  PubMed  PubMed Central  Google Scholar 

Vallée A, Gabet A, Grave C, Sorbets E, Blacher J, Olié V. Patterns of hypertension management in France in 2015: the ESTEBAN survey. J Clin Hypertens Greenwich Conn. 2020;22(4):663–72.

Article  Google Scholar 

Lecoffre C, Perrine AL, Blacher J, Olié V. LDL cholesterol in adults in metropolitan France: mean concentration, awareness and treatment in 2015, and trends since 2006. Bull Épidémiologique Hebd. 2018;37:710–8.

Google Scholar 

Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37. 2010/08/28 ed.

Article  CAS  PubMed  Google Scholar 

Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, et al. Treatment adherence and its impact on disease-free survival in the breast international group 1–98 trial of Tamoxifen and Letrozole, alone and in sequence. J Clin Oncol. 2016;34(21):2452–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yussof I, Mohd Tahir NA, Hatah E, Mohamed SN. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. Breast Edinb Scotl. 2022;62:22–35.

Article  Google Scholar 

Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8.

Article  CAS  PubMed  Google Scholar 

Muntner P, Yun H, Sharma P, Delzell E, Kent ST, Kilgore ML, et al. Ability of low antihypertensive medication adherence to predict statin discontinuation and low statin adherence in patients initiating treatment after a coronary event. Am J Cardiol. 2014;114(6):826–31.

Article  PubMed  Google Scholar 

Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882-887.e1.

Article  PubMed  Google Scholar 

Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc Med. 2014;24(7):285–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–62.

Article  PubMed  Google Scholar 

Rey G, Jougla E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997–2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;22(9):33.

Article  Google Scholar 

Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–74.

Article  PubMed  Google Scholar 

Lehmann A, Aslani P, Ahmed R, Celio J, Gauchet A, Bedouch P, et al. Assessing medication adherence: options to consider. Int J Clin Pharm. 2014;36(1):55–69.

Article  PubMed  Google Scholar 

Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457–64.

PubMed  PubMed Central  Google Scholar 

Moon Z, Moss-Morris R, Hunter M, Carlisle S, Hughes L. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017;11:305–22.

Article  PubMed  PubMed Central  Google Scholar 

Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(24):4027–34.

Article  Google Scholar 

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.

Article  Google Scholar 

Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(8):2301–8.

Article  Google Scholar 

Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601–9.

Article  PubMed  PubMed Central  Google Scholar 

Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244–56.

Article  PubMed  PubMed Central  Google Scholar 

Abdel-Qadir H, Fang J, Lee DS, Tu JV, Amir E, Austin PC, et al. Importance of considering competing risks in time-to-event analyses. Circ Cardiovasc Qual Outcomes. 2018;11(7):e004580.

Article  PubMed  PubMed Central  Google Scholar 

Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010;58(4):783–7.

Article  PubMed  PubMed Central  Google Scholar 

Kumamaru H, Lee M, Choudhry N, Dong YH, Krumme A, Khan N, et al. Using previous medication adherence to predict future adherence. J Manag Care Spec Pharm. 2018;1(24):1146–55.

Google Scholar 

Majd Z, Mohan A, Abughosh SM. Using group-based trajectory modeling to characterize the association of past ACEIs/ARBs adherence with subsequent statin adherence patterns among new statin users. J Am Pharm Assoc. 2021;61(6):829-837.e2.

Article  CAS  Google Scholar 

Majd Z, Mohan A, Paranjpe R, Abughosh S. Identifying adherent patients to newly initiated statins using previous adherence to chronic medications. J Manag Care Spec Pharm. 2021;1(27):186–97.

Google Scholar 

Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. BMJ Open. 2017;7(1):e014287.

Article  PubMed  PubMed Central  Google Scholar 

Koné AP, Scharf D. Prevalence of multimorbidity in adults with cancer, and associated health service utilization in Ontario, Canada: a population-based retrospective cohort study. BMC Cancer. 2021;21(1):406.

Article  PubMed  PubMed Central  Google Scholar 

Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, et al. Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2012;21(7):1115–25.

Article  Google Scholar 

Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM,